BLA 125545 · Hospira INC
Retacrit
Epoetin Alfa-Epbx · Injection
Last checked: Nov 20, 2026Latest source record: Jun 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
May 15, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
593
243 Phase 3, 14 recruiting
FAERS reports
2,244
1,516 serious, 494 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE See full prescribing information for complete boxed warning. Chronic Kidney Disease: • In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL ( 5.1 ). • No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks ( 2.2 ). • Use the lowest RETACRIT dose sufficient to reduce the need for red blood cell (RBC) transfusions ( 5.1 ). Cancer: •...
What it is approved for
From the label in effect Jun 22, 2025.
RETACRIT is an erythropoiesis-stimulating agent (ESA) indicated for: • Treatment of anemia due to o Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). o Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). o The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). • Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use RETACRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). RETACRIT is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). • In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). • In patients undergoing cardiac or vascular surgery ( 1.5 ). • As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). 1.1 Anemia Due to Chronic Kidney Disease RETACRIT is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion. 1.2 Anemia Due to Zidovudine in Patients with HIV Infection RETACRIT is indicated for the treatment of anemia due to zidovudine administered at ≤ 4,200 mg/week in patients with HIV infection with...
Mechanism: Epoetin alfa products stimulate erythropoiesis by the same mechanism as endogenous erythropoietin.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 30, 2020 Supplement 5 · Efficacy LabelLetter
- May 15, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
5 products under this application
- RETACRIT · EPOETIN ALFA-EPBX 40,000UNITS/ML · INJECTABLE, INJECTION · Prescription
- RETACRIT · EPOETIN ALFA-EPBX 4,000UNITS/ML · INJECTABLE, INJECTION · Prescription
- RETACRIT · EPOETIN ALFA-EPBX 2,000UNITS/ML · INJECTABLE, INJECTION · Prescription
- RETACRIT · EPOETIN ALFA-EPBX 10,000UNITS/ML · INJECTABLE, INJECTION · Prescription
- RETACRIT · EPOETIN ALFA-EPBX 3,000UNITS/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Epoetin Alfa" as an intervention, any sponsor and status, largest first.
- Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00093015 · 4,038 participants · Start Aug 1, 2004 · Primary completion Mar 1, 2009
Drug: Placebo; darbepoetin alfa · For: Kidney Disease; Diabetes Mellitus; Anemia
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02876835 · 3,872 participants · Start Sep 27, 2016 · Primary completion Apr 19, 2021
Drug: Daprodustat; Darbepoetin alfa and 2 more · For: Anaemia
Sites: Andalusia, Alabama; Birmingham, Alabama; Huntsville, Alabama · 574 sites in all
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)Pivotal-lookingCompleted
Akebia TherapeuticsIndustry
NCT02892149 · 3,554 participants · Start Aug 2016 · Primary completion Jan 16, 2020
Drug: Vadadustat; Darbepoetin alfa · For: Anemia; Dialysis-Dependent Chronic Kidney Disease
Sites: Huntsville, Alabama; Mesa, Arizona; Pine Bluff, Arkansas · 278 sites in all
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02879305 · 2,964 participants · Start Sep 28, 2016 · Primary completion Nov 9, 2020
Drug: Daprodustat; rhEPO and 2 more · For: Anaemia; Aspergillosis, Allergic Bronchopulmonary
Sites: Huntsville, Alabama; Pine Bluff, Arkansas; Anaheim, California · 462 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00773513 · 2,825 participants · Start Dec 12, 2008 · Primary completion Jul 27, 2017
Drug: Darbepoetin Alfa; Epoetin Alfa and 2 more · For: Chronic Renal Anemia
Sites: Buenos Aires, Argentina; CABA, Argentina; Gosford, Australia · 196 sites in all
- Blood Management in Orthopedic SurgeryPivotal-lookingCompleted
Sanquin Research & Blood Bank DivisionsAcademic, hospital or other
NCT00998088 · 2,598 participants · Start May 2004 · Primary completion Sep 2009
Drug: erythropoietin · For: Osteoarthritis
Sites: Amsterdam, Netherlands; Dordrecht, Netherlands; Gouda, Netherlands · 4 sites in all
- Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ChemotherapyPivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT00858364 · 2,549 participants · Start Jul 17, 2009 · Primary completion Jun 7, 2017
Drug: Darbepoetin alfa; Placebo · For: Non-Small Cell Lung Cancer; Anemia; Cancer and 1 more
Sites: Anniston, Alabama; Birmingham, Alabama; Anchorage, Alaska · 566 sites in all
- ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA PatientsPivotal-lookingRecruiting
Australian and New Zealand Intensive Care Research CentreAcademic, hospital or other
NCT04588311 · 2,500 participants (planned) · Start Nov 9, 2020 · Primary completion Dec 31, 2026
Drug: Epoetin Alfa 40000 UNT/ML; Sodium Chloride 0.9% · For: Trauma; Traumatic Injury; Traumatic Brain Injury and 5 more
Sites: Camperdown, Australia; Darlinghurst, Australia; Kogarah, Australia · 41 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death416
- off label use329
- haemoglobin decreased167
- anaemia109
- asthenia85
- diarrhoea80
- fatigue78
- hospitalisation73
- product dose omission issue61
- nausea58
- pneumonia58
- malaise54
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 14 |
| 2014 | 13 |
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 39 |
| 2019 | 151 |
| 2020 | 349 |
| 2021 | 327 |
| 2022 | 381 |
| 2023 | 402 |
| 2024 | 199 |
| 2025 | 166 |
| 2026 | 173 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Retacrit (Epoetin Alfa-Epbx)
2024 spending
$27.1M
Beneficiaries
13,155
47,809 claims
Per beneficiary
$2,062
$205.99 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $23,796,443 |
| 2021 | $31,828,561 |
| 2022 | $32,855,063 |
| 2023 | $24,529,471 |
| 2024 | $27,125,959 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
Chen N, Hao C, Liu BC, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Singh AK, Carroll K, Perkovic V, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
Della Porta MG, Garcia-Manero G, Santini V, et al. · Lancet Haematol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Chung EY, Palmer SC, Saglimbene VM, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D).
Gang S, Khetan P, Varade D, et al. · Am J Nephrol 2022 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.